Comparative Pharmacology
Head-to-head clinical analysis: CARNEXIV versus QUINORA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARNEXIV versus QUINORA.
CARNEXIV vs QUINORA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARNEXIV is a formulation of carbidopa and levodopa; levodopa is converted to dopamine in the brain, replenishing depleted dopamine in the striatum, while carbidopa inhibits peripheral decarboxylation of levodopa, increasing central availability.
Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
1 mg intravenously once daily for 7 days, followed by 1 mg orally once daily for 7 days.
325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged in renal impairment (up to 24-36 hours with CrCl <30 mL/min)
5-7 hours; prolonged in hepatic impairment (up to 12-15 hours) and in elderly patients.
Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 25-30%)
Primarily hepatic (biliary) excretion into feces (~80-90%); renal excretion of unchanged drug accounts for ~10-20%.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent